LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

45.96 4.98

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

43.5

Максимум

46.22

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+24.63% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	139M 3.4B
Предишно отваряне	40.98
Предишно затваряне	45.96

Настроения в новините

By Acuity

50%

166 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.12.2025 г., 23:54 ч. UTC

Значими двигатели на пазара

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22.12.2025 г., 19:08 ч. UTC

Придобивния, сливания и поглъщания

Correction to Alphabet to Buy Intersect Article

22.12.2025 г., 17:21 ч. UTC

Придобивния, сливания и поглъщания

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22.12.2025 г., 16:46 ч. UTC

Придобивния, сливания и поглъщания

Alphabet to Buy Intersect for $4.75 Billion in Cash

22.12.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline as Yen Rebounds -- Market Talk

22.12.2025 г., 23:42 ч. UTC

Пазарно говорене

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22.12.2025 г., 22:31 ч. UTC

Печалби

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22.12.2025 г., 22:31 ч. UTC

Печалби

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22.12.2025 г., 22:30 ч. UTC

Печалби

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

22.12.2025 г., 21:37 ч. UTC

Придобивния, сливания и поглъщания

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22.12.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22.12.2025 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

Capricorn to Acquire Prospective Package From Tempest Minerals

22.12.2025 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22.12.2025 г., 20:54 ч. UTC

Придобивния, сливания и поглъщания

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22.12.2025 г., 20:52 ч. UTC

Придобивния, сливания и поглъщания

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22.12.2025 г., 20:09 ч. UTC

Пазарно говорене

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22.12.2025 г., 19:56 ч. UTC

Пазарно говорене

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22.12.2025 г., 19:49 ч. UTC

Придобивния, сливания и поглъщания

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22.12.2025 г., 19:23 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Easing in Early December -- Market Talk

22.12.2025 г., 19:23 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.12.2025 г., 19:02 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

22.12.2025 г., 19:02 ч. UTC

Пазарно говорене

Precious Metals Climb to New Heights -- Market Talk

22.12.2025 г., 18:45 ч. UTC

Пазарно говорене

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22.12.2025 г., 18:30 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22.12.2025 г., 18:23 ч. UTC

Придобивния, сливания и поглъщания

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

22.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

22.12.2025 г., 17:06 ч. UTC

Придобивния, сливания и поглъщания

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

24.63% нагоре

12-месечна прогноза

Среден 54.96 USD 24.63%

Висок 65 USD

Нисък 44 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

166 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.